Sagimet Biosciences (STU:0O2) NonCurrent Deferred Income Tax: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:0O2 Sagimet Biosciences Inc STU:0O2
18 GF Score
Price €6.40
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Sagimet Biosciences NonCurrent Deferred Income Tax?

Sagimet Biosciences STU:0O2 -4.48% 18 NonCurrent Deferred Income Tax is €0.00 Mil as of Mar. 2026. GuruFocus rates STU:0O2 with a GF Score™ of 18/100 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Non-Current Deferred Income Tax represents the non-current portion of deferred income taxes, which is the difference in income recognition between tax laws and the accounting methods.

Sagimet Biosciences's non-current deferred income tax for the quarter that ended in Mar. 2026 was €0.00 Mil.

Sagimet Biosciences NonCurrent Deferred Income Tax Related Terms

Sagimet Biosciences NonCurrent Deferred Income Tax Historical Data

* Premium members only.

The historical data trend for Sagimet Biosciences's NonCurrent Deferred Income Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sagimet Biosciences NonCurrent Deferred Income Tax Chart

Sagimet Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Income Tax
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Sagimet Biosciences Quarterly Data
Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Income Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:0O2
18GF Score
Sagimet Biosciences Inc STU:0O2
NonCurrent Deferred Income Tax is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Income Tax of €0.00 Mil mean?
Sagimet Biosciences (STU:0O2) has a NonCurrent Deferred Income Tax of €0.00 Mil as of Mar. 2026. Non-Current Deferred Income Tax is the difference in income recognition between tax laws and the accounting methods, being realized beyond 12 months. View historical data on Sagimet Biosciences and its competitors.
Is Sagimet Biosciences' NonCurrent Deferred Income Tax too high?
Sagimet Biosciences' current NonCurrent Deferred Income Tax is €0.00 Mil. Overall, Sagimet Biosciences has a GF Score™ of 18/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' NonCurrent Deferred Income Tax compare to EDIT and AUTL?
Sagimet Biosciences' NonCurrent Deferred Income Tax of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Income Tax for a Biotechnology company?
A good NonCurrent Deferred Income Tax depends on the Biotechnology industry context. However, NonCurrent Deferred Income Tax should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Income Tax mean?
A high NonCurrent Deferred Income Tax can signal that a stock is expensive relative to its fundamentals. Non-Current Deferred Income Tax is the difference in income recognition between tax laws and the accounting methods, being realized beyond 12 months. View historical data on Sagimet Biosciences and its competitors. Sagimet Biosciences's current NonCurrent Deferred Income Tax is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Sagimet Biosciences (STU:0O2) is currently considered Modestly Overvalued. The current NonCurrent Deferred Income Tax is €0.00 Mil. Sagimet Biosciences' overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Income Tax calculated?
NonCurrent Deferred Income Tax is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current NonCurrent Deferred Income Tax is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sagimet Biosciences Business Description

Other Exchanges SGMT:USA
Address 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
18GF Score

Get the complete analysis for STU:0O2

NonCurrent Deferred Income Tax is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.40
Price